Compare AbbVie Inc (ABBV) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs VanEck Gold Miners ETF — how do they compare? AbbVie Inc trades at $256.5 (market cap $459.82B), while VanEck Gold Miners ETF trades at $99.39. The key difference: AbbVie Inc pays a 2.66% dividend while VanEck Gold Miners ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GDX | |
|---|---|---|
Market Cap | $459.82B | — |
Sector | Health | — |
52-Week High | $265.97 | $115.84 |
52-Week Low | $197.38 | $64.53 |
Enterprise Value | $524.07B | — |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $256.34, down 2.05% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth with 2025 revenue reaching $61.16B and has beaten earnings expectations for three consecutive quarters. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity support the bullish case, though high valuation ratios and patent cliff concerns remain considerations.
The outlook remains positive with 72% analyst buy ratings and a $281.41 consensus price target representing 9.8% upside. Key opportunities include continued growth from Skyrizi and Rinvoq offsetting Humira declines, while risks involve patent expirations in the 2030s and regulatory challenges. The stock offers dividend growth with a $1.73 quarterly payment and appears positioned for sustained expansion despite near-term volatility.
GDX (VanEck Gold Miners ETF) trades at $97.59, up 3.08% on the day, with a bullish technical outlook supported by moving averages and oscillators. The ETF is positioned near resistance at $97-$100, with support at $93-$92. Recent news highlights gold's strength and miner catch-up potential, though key financial ratios are not provided in the data.
The outlook for GDX is positive, driven by gold price momentum and technical breakout potential targeting $115. Risks include gold price volatility, Fed policy shifts, and miner underperformance relative to bullion. Analyst sentiment is generally bullish, but investors should monitor gold market dynamics and ETF-specific flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
